Biocardia Cardiamp Chronic Myocardial Ischemia Trial Top Line Data Of Roll-In Cohort Show Improved Exercise Tolerance
Sept 18 (Reuters) - BioCardia Inc BCDA.O:
BIOCARDIA: CARDIAMP CHRONIC MYOCARDIAL ISCHEMIA TRIAL TOP LINE DATA OF ROLL-IN COHORT SHOW IMPROVED EXERCISE TOLERANCE
BIOCARDIA INC - REDUCED ANGINA EPISODES AT SIX-MONTH PRIMARY FOLLOW-UP
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Tradingkey







